Search results for " psychosis"

showing 10 items of 120 documents

The long-term use of psychiatric services within the Open Dialogue treatment system after first-episode psychosis

2017

AbstractOpen Dialogue is a family-oriented early intervention model for mental health problems developed in the health district of Western Lapland, Finland. In the present study, the aim was to describe how psychiatric services were used in Western Lapland after decades of first-episode psychosis services, and to analyze how baseline characteristics were related to re-admission rates and the total duration of psychiatric treatment in geographical area where Open Dialogue approaches were developed and efforts made to systematically apply them to all psychiatric treatments. The data were obtained from the medical histories of patients who had first-episode psychosis in 1992–2005 and who lived…

Psychosismedicine.medical_specialty03 medical and health sciences0302 clinical medicineIntervention (counseling)First episode psychosismedicinefirst-episode psychosisPsychiatryBaseline (configuration management)ta515psychosesTreatment systemlong-term treatment patternsbusiness.industryopen-dialogue approachneed-adapted approachmedicine.diseaseMental health030227 psychiatryTerm (time)mental disordersPsychiatry and Mental healthlong-term careCatchment areabusiness030217 neurology & neurosurgeryPsychosis
researchProduct

Migration history and risk of psychosis: results from the multinational EU-GEI study.

2022

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme.

Psychosismedicine.medical_specialtyESTUDOS DE CASOS E CONTROLESEthnic groupLogistic regressionIMMIGRANTSFAMILY-HISTORYfirst-generation migrantsOdds03 medical and health sciences0302 clinical medicineFirst-episode psychosifirst-generation migrantSCHIZOPHRENIAmedicinemigration adversities[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]1ST-EPISODE PSYCHOSISINTERNAL MIGRATIONApplied PsychologyCumulative effectComputingMilieux_MISCELLANEOUSmigration historypsychosis riskbusiness.industryPublic healthmigration adversitieSDG 10 - Reduced InequalitiesFirst-episode psychosismedicine.diseaseCHILDHOOD TRAUMA030227 psychiatry3. Good healthETHNICITYPsychiatry and Mental healthsocial disadvantagesSchizophreniaMultinational corporation/dk/atira/pure/sustainabledevelopmentgoals/reduced_inequalities1ST-CONTACT INCIDENCE[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]businesssocial disadvantages.MENTAL-HEALTHSOCIAL DISADVANTAGE030217 neurology & neurosurgeryDemography
researchProduct

A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis

2021

Introduction: There is evidence that early intervention contributes to improving the prognosis and course of first-episode psychosis (FEP). However, further randomised treatment clinical trials are needed. Objectives: The aim of this study was to compare the efficacy of a combined clinical treatment involving Cognitive Behavioural Therapy (CBT) as an adjunctive to treatment-as-usual (TAU) (CBT+TAU) versus TAU alone for FEP. Patients and methods: In this multicentre, single-blind, randomised controlled trial, 177 participants were randomly allocated to either CBT+TAU or TAU. The primary outcome was post-treatment patient functioning. Results: The CBT+TAU group showed a greater improvement in…

Psychosismedicine.medical_specialtyanimal structuresPronòstic mèdicHealth Toxicology and MutagenesisPsicosiDiseasebehavioral disciplines and activitiesArticlelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawIntervention (counseling)Internal medicinemental disordersmedicineScopusHumansSingle-Blind Methodfirst-episode psychosisClinical treatmenttreatmentCognitive Behavioral Therapybusiness.industryStandard treatmentRPublic Health Environmental and Occupational HealthPsychosesCognitionmedicine.diseasePrognosisCombined Modality Therapy030227 psychiatryClinical trialTreatment Adherence and Complianceearly interventionTreatment OutcomePsychotic DisordersJCRSchizophreniaoutcomeMedicineEsquizofrèniabusinessrandomised controlled trial030217 neurology & neurosurgeryInternational Journal of Environmental Research and Public Health
researchProduct

Pre-training inter-rater reliability of clinical instruments in an international psychosis research project.

2021

International audience

Research designPsychosisINFORMATIONIMPACTApplied psychologyMEDLINEAssessor selection Pre-training inter-rater reliability Psychosis instruments03 medical and health sciences0302 clinical medicineMedicineHumansBiological PsychiatryComputingMilieux_MISCELLANEOUSObserver VariationREPRODUTIBILIDADE DE RESULTADOSbusiness.industryPre-training inter-rater reliabilityReproducibility of Resultsmedicine.disease030227 psychiatryPsychiatry and Mental healthInter-rater reliabilityAssessor selectionTRIALSPsychotic DisordersResearch Design[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]MEASUREMENT ERRORbusinessObserver variation030217 neurology & neurosurgeryPsychosis instrumentsSchizophrenia research
researchProduct

Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

2022

AbstractBackgroundThere is evidence that environmental and genetic risk factors for schizophrenia spectrum disorders are transdiagnostic and mediated in part through a generic pathway of affective dysregulation.MethodsWe analysed to what degree the impact of schizophrenia polygenic risk (PRS-SZ) and childhood adversity (CA) on psychosis outcomes was contingent on co-presence of affective dysregulation, defined as significant depressive symptoms, in (i) NEMESIS-2 (n = 6646), a representative general population sample, interviewed four times over nine years and (ii) EUGEI (n = 4068) a sample of patients with schizophrenia spectrum disorder, the siblings of these patients and controls.ResultsT…

RiskMultifactorial InheritancePsychosisHallucinationsAffective pathwayCLINICAL PSYCHOSISNEGATIVE SYMPTOMSDelusions03 medical and health sciences0302 clinical medicineMENTAL-HEALTH SURVEYchildhood adversityAffective dysregulationHumansMedicinegeneticspsychosisGenetic riskApplied Psychology1ST EPISODE PSYCHOSISGENERAL-POPULATIONbusiness.industryPSYCHIATRIC-DISORDERSSHORT-FORMAbsolute risk reductionNETWORK APPROACHIdeationmedicine.diseaseCHILDHOOD TRAUMA030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaSCHIZOPHRENIA SPECTRUM DISORDERSPolygenic risk scorebusinessenvironment030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyPsychological Medicine
researchProduct

Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis

2023

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme.

SCHIZOPHRENIA SPECTRUMmedicine.medical_specialtyGENESpolygenic riskfirst-episode psychosiILLNESSinteraction contrast ratioChildhood traumaDOPAMINEFirst episode psychosisSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.MALTREATMENTMedicinefirst-episode psychosisABUSEPsychiatrySettore MED/25 - PsichiatriaApplied PsychologyTRAUMAENVIRONMENTbusiness.industrymedicine.diseaseschizophreniaPsychiatry and Mental healthSchizophreniaRELIABILITYPolygenic risk scoresynergistic effectsbusinessPsychological medicine
researchProduct

Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and …

2021

AbstractBackgroundFirst episode psychosis (FEP) patients who use cannabis experience more frequent psychotic and euphoric intoxication experiences compared to controls. It is not clear whether this is consequent to patients being more vulnerable to the effects of cannabis use or to their heavier pattern of use. We aimed to determine whether extent of use predicted psychotic-like and euphoric intoxication experiences in patients and controls and whether this differs between groups.MethodsWe analysed data on patients who had ever used cannabis (n = 655) and controls who had ever used cannabis (n = 654) across 15 sites from six countries in the EU-GEI study (2010–2015). We used multiple regres…

SYMPTOMSPoison control0302 clinical medicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.substance abuseApplied PsychologyPOPULATIONRISKeducation.field_of_studybiologyHuman factors and ergonomicsCannabis usePsychotomimeticSubstance abusePsychiatry and Mental healthSchizophreniaPsychotic-like experiencepsychotomimeticmedicine.drugmedicine.medical_specialtyDISORDERSPopulationFrequency of use03 medical and health sciencesFirst episode psychosisInjury preventionmedicineHumansAssociation (psychology)PsychiatryeducationSettore MED/25 - PsichiatriaDELUSIONAL IDEATIONEffects of cannabisMETAANALYSISCannabisCannabinoid Receptor Agonistsbusiness.industryPsychotic-like experiencesbiology.organism_classificationmedicine.disease030227 psychiatryschizophreniaMulti nationalPsychotic DisordersHallucinogensPOTENCYCannabisbusiness030217 neurology & neurosurgery
researchProduct

Perceived stigma in patients affected by psychosis: Is there an impact on relapse?

2016

Introduction The World Health Organization (WHO) considers stigma of mental illness as a crucial problem (WHO, 2001). Stigma contributes to the onset (Morgan et al., 2010) and the outcome of people affected by schizophrenia (Himan, 2015). Objectives To evaluate the perception of patients affected by psychotic disorders of being stigmatized by the community. Aims To compare the perception of stigma among subgroups of patients at different stage of their disorder. Methods Thirty-five patients affected by a first-episode of psychosis (FEP) and 96 patients affected by chronic psychosis were recruited. The Devaluation of Consumers Scale (DCS) and the Devaluation of Consumer Families Scale (DCFS)…

Settore M-PSI/08 - Psicologia ClinicaSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.STIGMA PSYCHOSISSettore MED/25 - Psichiatria
researchProduct

What does augment the risk to use cannabis on an everyday-basis in psychotic patients?

2017

Introduction There are strong enough evidences of the fact that risk of psychosis is augmented by cannabis use. In a recent analysis, the strongest predictor of case-control status was daily-skunk use, i.e. the ORs for skunk users increase with the frequency of use5. We know also that FEP who smoked cannabis in their lifetime are less neuropsychologically impaired i.e. they have better premorbid and current IQ6. In this study we wanted to test what augments the probability to be everyday users, taking into account premorbid social and academic adjustment and cognition as predictors, along with age at first cannabis-use and % of THC in cannabis used. Methods The sample was made of 834 First …

Settore M-PSI/08 - Psicologia ClinicaSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.Settore MED/25 - Psichiatriacannabis abuse age at first use psychosis
researchProduct

FIRST EPISODE PSYCHOSIS PATIENTS WHO USED CANNABIS DEVELOP THEIR ILLNESS AT A SIGNIFICANTLY YOUNGER AGE THAN THOSE WHO NEVER USED CONSISTENTLY ACROSS…

2018

Background: Patients presenting to psychiatric services with their first episode of psychosis (FEP) report higher rates of previous cannabis use than the general population (Donoghue et al., 2011; Myles, Myles and Large, 2016). Evidence suggested that patients suffering from psychosis with a history of cannabis use have an earlier age of onset of psychosis (AOP) than those who never used it (Di Forti et al., 2013). We aim to investigate if the reported association between use of cannabis and AOP is consistent across different countries, once having taken into account different patterns of cannabis use (i.e. frequency of use and age at first use). Methods: We analysed data on patterns of lif…

Settore M-PSI/08 - Psicologia ClinicaSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.age of onset psychosis cannabisSettore MED/25 - Psichiatria
researchProduct